Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.
about
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)A review of malaria vaccine clinical projects based on the WHO rainbow tableA host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMPAdenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsProtection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues.Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraSafety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 proteinSterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesA DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialDNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.Fate of TLR-1/TLR-2 agonist functionalised pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro.A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.Progress towards achieving new vaccine and vaccination goals.Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Particle-mediated DNA vaccine delivery to the skin.Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum EpitopesMalaria vaccines in development.Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.DNA vaccines against tropical parasitic diseases.Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.Prospects for developing an effective vaccine against ocular herpes simplex virus infection.Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.Pre-erythrocytic malaria vaccines: towards greater efficacy.Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cellsClinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNAPreclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response
P2860
Q21034050-4EEB6759-22B8-4005-A0F9-C96448704738Q21034112-7610D9FD-2EDB-4689-A79F-E00A5E6EE6BBQ24642631-0B4BA3F6-13AA-431D-9C8B-90BB0D82612BQ28744149-62C853AD-C393-4EED-BE07-7128C37AC8A6Q33303670-CAC02041-EFA1-4B24-8CD1-A739E249BEAFQ33400526-3D794350-3AE4-4A93-8530-BD7ADA49F0E2Q33768911-FCC4FCEC-8079-46DF-9B17-C69471B5A13AQ33818084-156D9DD5-A3DA-4B76-B98D-F49E1E429323Q33935092-AC01D6BF-C922-45B6-8F25-5E45CBF96644Q34125450-7F434572-B19D-4891-847F-2F0D346BFB99Q34128586-CA63A47B-2D65-4E7B-9D9E-D37318EB519AQ34165879-4539E9F0-E3C6-4F3D-9AF8-719F43CE2CA6Q34571072-C2784F5B-5BF6-4E89-92EC-5B00A46E87EDQ34606356-78C951F4-55BD-462D-98EB-DD79092A460AQ34774547-A0D92AFD-1617-4FAD-A651-3DC9492C7483Q34852418-35C53280-646A-4280-9C43-4671653FF324Q34960453-8C37F669-A8BB-4BA7-9FE6-12A39CDA7354Q35073970-91527E76-9EF2-48DC-97A4-65D8290F4F4CQ35093445-7C355595-D00A-4E71-9962-1FA04FB29CF0Q35161394-F12B9FAC-AA4E-4E70-93CE-2ACE9364C560Q35611969-0A83F864-5AC0-4298-BD93-5305C32BD6E6Q35790864-F2027F69-7855-4F28-9EE9-9F7812021EEEQ35826388-C071A385-C6B5-464B-9C46-EEF000512E6BQ35857581-5EC0A602-41C8-4212-B27E-3CB5D4E0FCAEQ35949699-5F297540-8975-48FA-B5E3-3DA6C29D2311Q36092323-085D7E71-5E22-476D-9C1E-53B99423615CQ36141610-382CB201-3D34-4C21-B253-69ED5C12D9A0Q36151198-1D536D01-6729-4BE3-83E8-1608DC5B9599Q36219634-09A2F14D-8C76-4CAF-B8D1-1E32F095F4D6Q36229051-B1442209-F131-407A-BFFC-933BC8B8948EQ36238733-461790A8-8043-404B-874F-D66CA8E9F459Q36285998-C6326E9D-5A59-4684-B6C8-18CDC78D9DBCQ36311038-BECBE163-1DB2-4B36-8CEB-0E6696DC2965Q36383811-DABA4190-81EF-4771-B2D2-208C188E6219Q36403400-003539F6-9C4A-438E-81DA-4281F1D2D1FEQ36412657-CC6505A9-5B59-4962-A244-6C485D5F98CEQ36509697-AF6366C1-2EEC-40CF-9860-84884295AC21Q36694820-67FEEFDD-3C93-42C9-B55E-7B66EC9A72CAQ36694825-12FD1388-B4A4-4896-B577-5AF476AF5C6FQ36752152-4E7E8B84-BE40-4184-A574-881E720C0EA7
P2860
Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Induction of CD4(+) T cell-dep ...... mans by a malaria DNA vaccine.
@ast
Induction of CD4(+) T cell-dep ...... mans by a malaria DNA vaccine.
@en
type
label
Induction of CD4(+) T cell-dep ...... mans by a malaria DNA vaccine.
@ast
Induction of CD4(+) T cell-dep ...... mans by a malaria DNA vaccine.
@en
prefLabel
Induction of CD4(+) T cell-dep ...... mans by a malaria DNA vaccine.
@ast
Induction of CD4(+) T cell-dep ...... mans by a malaria DNA vaccine.
@en
P2093
P2860
P356
P1476
Induction of CD4(+) T cell-dep ...... umans by a malaria DNA vaccine
@en
P2093
D J Carucci
F M Baraceros
N Rahardjo
R C Hedstrom
P2860
P304
10817-10822
P356
10.1073/PNAS.181123498
P407
P577
2001-08-28T00:00:00Z